UK Business Secretary Greg Clark and Science Minister Sam Gyimah today opened the Cell and Gene Therapy Catapult’s (CGT Catapult) unique cell and gene therapy manufacturing center in Stevenage, UK. Backed by over £60 million ($84m) of UK Government investment from its Industrial Strategy, the center will support and develop the rapidly growing global cell and gene therapy industry in the UK while demonstrating the government’s modern Industrial Strategy in action. The center will also supply the network of world-first, UK-based Advanced Therapies Treatment Centres (ATTCs) formed as part of the government’s investment of £146 million ($204m) through its Industrial Strategy Challenge Fund in medicines manufacturing. Greg Clark commented: “We are determined to make the UK the most innovative nation in the world through our Industrial Strategy and its Grand Challenges, which is why we are investing a record £7 billion ($9.8 bn) in R&D by 2021, the highest increase in 40 years, and have committed to investing 2.4% of GDP on R&D by 2027.” For more information, visit ct.catapult.org.uk or http://www.gov.uk/innovate-uk.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.